Biotech KPO

biotechkpo.com

Biotech KPO specializes in outsourcing of Business Process that creates value for our clients. We help our clients optimize business process enhancing flexibility of their operation at substantial cost advantage. The company focuses on the high-end Biotechnology/ Life Sciences services. The services we provide are highly knowledge based, require highly skilled professionals and cover some of the critical knowledge management areas for our clients. Biotech KPO, team of Biotechnology Professional, providing these services from our state-of-art facility in New Delhi-India. India is a promising source of supply for talent for providing these services.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Research

BIGHAT BIOSCIENCES COMPLETES FIRST STAGE OF RESEARCH COLLABORATION WITH AMGEN

BigHat Biosciences, Inc. | January 12, 2022

news image

BigHat Biosciences, Inc., a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform, announced the successful completion of the first stage of a previously undisclosed research collaboration and licensing agreement with Amgen applying BigHat’s platform for multi-objective optimization of a next-generation antibody. BigHat’s antibody design platform integrates a high-speed characterization with AI/ML tech...

Read More

SPRUCE BIOSCIENCES CLOSES ON $88 MILLION SERIES B ROUND, ADVANCING CAH PROGRAM

BioSpace | February 20, 2020

news image

Spruce Biosciences, based in San Francisco, closed on a Series B financing round worth $88 million. The round was co-led by Omega Funds and Abingworth and supported by existing investors Novo Holdings and RiverVest Venture Partners. New investors included HealthCap Partners, Rock Springs Capital, Surveyor Capital (a Citadel company), Aisling Capital and Sands Capital. In September 2019, the company announced positive results from a Phase IIa, multicenter, 12-week clinical trial of tildacerfont f...

Read More

Research

TETRASCIENCE R&D DATA CLOUD SELECTED BY LEADING CLINICAL-STAGE BIOTECHNOLOGY COMPANY

TetraScience | September 03, 2021

news image

TetraScience, the R&D Data Cloud company, announced today that Zymeworks Inc. has selected the Tetra Data Platform (TDP) to standardize and automate scientific data flow. As a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics, Zymeworks' R&D engine generates and analyzes large amounts of scientific data in its quest to revolutionize drug design. "In order to take advantage of innovative data sc...

Read More

Cell and Gene Therapy

DYADIC ANNOUNCES A NIIMBL CORONAVIRUS GRANT UNDER THE WHITE HOUSE’S AMERICAN RESCUE PLAN

Dyadic International, Inc. | December 23, 2021

news image

Dyadic International, Inc. a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve access to biologic vaccines and drugs at flexible commercial scales, announced it is the recipient of one of thirty-two project grants awarded by the National Institute for Innovation in Manufacturing Biopharmaceuticals funded through the White House’s American Rescue ...

Read More
news image

Research

BIGHAT BIOSCIENCES COMPLETES FIRST STAGE OF RESEARCH COLLABORATION WITH AMGEN

BigHat Biosciences, Inc. | January 12, 2022

BigHat Biosciences, Inc., a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform, announced the successful completion of the first stage of a previously undisclosed research collaboration and licensing agreement with Amgen applying BigHat’s platform for multi-objective optimization of a next-generation antibody. BigHat’s antibody design platform integrates a high-speed characterization with AI/ML tech...

Read More
news image

SPRUCE BIOSCIENCES CLOSES ON $88 MILLION SERIES B ROUND, ADVANCING CAH PROGRAM

BioSpace | February 20, 2020

Spruce Biosciences, based in San Francisco, closed on a Series B financing round worth $88 million. The round was co-led by Omega Funds and Abingworth and supported by existing investors Novo Holdings and RiverVest Venture Partners. New investors included HealthCap Partners, Rock Springs Capital, Surveyor Capital (a Citadel company), Aisling Capital and Sands Capital. In September 2019, the company announced positive results from a Phase IIa, multicenter, 12-week clinical trial of tildacerfont f...

Read More
news image

Research

TETRASCIENCE R&D DATA CLOUD SELECTED BY LEADING CLINICAL-STAGE BIOTECHNOLOGY COMPANY

TetraScience | September 03, 2021

TetraScience, the R&D Data Cloud company, announced today that Zymeworks Inc. has selected the Tetra Data Platform (TDP) to standardize and automate scientific data flow. As a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics, Zymeworks' R&D engine generates and analyzes large amounts of scientific data in its quest to revolutionize drug design. "In order to take advantage of innovative data sc...

Read More
news image

Cell and Gene Therapy

DYADIC ANNOUNCES A NIIMBL CORONAVIRUS GRANT UNDER THE WHITE HOUSE’S AMERICAN RESCUE PLAN

Dyadic International, Inc. | December 23, 2021

Dyadic International, Inc. a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve access to biologic vaccines and drugs at flexible commercial scales, announced it is the recipient of one of thirty-two project grants awarded by the National Institute for Innovation in Manufacturing Biopharmaceuticals funded through the White House’s American Rescue ...

Read More